ADC Deals Are Up 1900% in 2026 — Here's the Data

Twenty ADC deals closed between February and August 2026 — a 1900% increase over the prior six-month period, which produced exactly one. That is not a typo. The comparison window of August 2025 to February 2026 was effectively a dead zone for ADC licensing, and what followed was the sharpest modality-specific deal surge we have tracked on Deal Benchmarks this year. The driver is straightforward: Big Pharma has run out of internal ADC pipeline to feed its commercial ambitions, and the bidding war for differentiated payloads, linkers, and next-generation conjugation platforms has arrived.

The Data — ADC Deal Activity, Period over Period

A 1900% move demands context. The prior trough wasn't random — it reflected a post-Enhertu hangover. After AstraZeneca and Daiichi Sankyo's deal reset expectations on ADC economics, the market spent late 2025 recalibrating what "fair" looked like for next-generation conjugates. Licensors held firm on valuations. Buyers balked. Deal flow froze. Then Q1 2026 broke the logjam, and the pent-up demand hit the market all at once.

What's Driving the Trend

Pipeline gaps at scale. GSK, Novartis, Pfizer, and Roche all face the same structural problem: their oncology franchises need ADC-class assets to defend market share against competitors who already have them. Pfizer's Padcev integration is maturing. AstraZeneca's Enhertu dominance continues to pressure peers. For companies without a commercially validated ADC franchise, the window to build one through licensing is narrowing — and they know it. The result is aggressive deal-making with compressed timelines. Multiple sources indicate that several of the 20 deals in this window went from first meeting to signed term sheet in under 90 days.

Platform plays over single-asset bets. The 2026 ADC licensing wave is qualitatively different from 2023–2024 deal activity. Buyers are no longer content to license a single candidate. They want access to conjugation platforms, proprietary linker-payload combinations, and site-specific conjugation technologies that can generate multiple clinical candidates. The Novartis–Myricx Bio transactions — two separate deals signed on the same day totaling $2.6B in potential deal value — are the clearest signal. Novartis didn't buy one program. It locked up a technology stack. That pattern is repeating across the dataset.

Capital markets are cooperating. Biotech financing conditions in H1 2026 have been the most favorable since 2021. The XBI is up roughly 18% year-to-date, and crossover rounds for preclinical ADC companies are closing at $80M–$150M pre-money valuations. This gives licensors leverage: they can credibly threaten to fund programs internally rather than accept suboptimal deal terms. Buyers who wait are paying more — or losing access entirely.

Notable Deals

Hansoh–GSK ($185M upfront / $1.7B TDV): This is the anchor deal of the cycle. GSK paid a $185M upfront — among the highest for a non-US ADC originator in 2026 — signaling that geography is no longer a discount factor for differentiated ADC assets. Hansoh's ADC portfolio has generated significant clinical data in solid tumors, and GSK clearly concluded that waiting for Phase 2 readouts would only increase the price. The 10.9% upfront-to-TDV ratio sits right at the median for oncology licensing deals tracked on our Deal Benchmarks platform, suggesting GSK negotiated within market norms despite the competitive pressure.

Myricx Bio–Novartis ($1.1B + $1.5B TDV across two deals): Two deals, one day, $2.6B in aggregate potential value. Novartis structured these as separate agreements — likely reflecting distinct payload classes or indication-specific rights — but the strategic intent is singular: build a proprietary ADC engine. Myricx Bio's novel conjugation chemistry appears to be the draw. For a company with limited public profile before July 2026, this is a validation event that will reshape how the market values early-stage ADC platform companies. The absence of disclosed upfronts suggests equity components or milestone-heavy structures, which we are monitoring.

Biocytogen–Whitehawk ($500M TDV): Whitehawk's emergence as a repeat buyer — two Biocytogen deals on the same date — points to a growing class of mid-cap and specialty pharma companies entering the ADC space. These are not the traditional Big Pharma acquirers. They are building focused oncology portfolios and using ADC licensing as the backbone. This democratization of the ADC deal market is expanding the buyer pool and sustaining upward pressure on valuations.

What This Means for BD Teams Right Now

Sellers: this is your market — but the window has a shelf life. Twenty deals in six months means buyers are actively competing for assets. If you have a differentiated ADC platform or clinical-stage conjugate, you are negotiating from strength. Upfront payments are rising, and buyers are conceding broader milestone structures to win competitive processes. Use the Ambrosia calculator to benchmark your term sheet against the current deal environment before you accept the first offer.

Buyers: move fast or pay a premium later. The data is unambiguous. Waiting through the 2025 trough did not produce bargains — it produced a 1900% surge in competitive deal flow. The best ADC platforms are being locked up now, often in multi-program agreements that remove them from the market entirely. If your oncology strategy requires ADC capabilities, delaying diligence by even one quarter will cost you. The Novartis playbook — two deals, same day, same partner — is the new template for securing platform access before competitors do.

Deal structures are shifting. We are seeing three structural trends across ADC licensing 2026: (1) higher upfronts as a percentage of TDV, driven by seller leverage and competitive processes; (2) platform-level deals rather than single-asset licenses, reflecting buyer demand for pipeline optionality; and (3) equity components embedded in early-stage transactions where upfront cash is replaced by stakes in the licensor. BD teams should be modeling all three structures in parallel. The days of a clean, single-asset option deal with a modest upfront and back-loaded milestones are not gone — but they are increasingly reserved for undifferentiated assets that nobody is competing for.

Benchmark your deal against current market rates. Whether you are structuring an ADC out-license or evaluating an inbound term sheet, the market has moved. Use the Ambrosia calculator to pressure-test your economics against the 20 deals that closed this cycle and see where your terms sit relative to the new baseline.